Ocrelizumab-induced colitis—critical review and case series from a Romanian cohort of MS patients

Ocrelizumab-induced colitis—critical review and case series from a Romanian cohort of MS patients

BackgroundWidespread use of ocrelizumab, an anti-CD20 monoclonal antibody, for treating patients with multiple sclerosis (MS), has led to an increase in reported adverse events following real-world observation. Among these, drug-induced colitis is a rare, but severe side effect, prompting a recent F...

Full description

Saved in:
Bibliographic Details
Main Authors: Ileana Maria Vodă, Vlad Eugen Tiu, Luiza Răuță, Paul Ciucur, Andreea Ioana Mușuroi, Alina Flavia Tomescu, Nicoleta Laura Humă, Florin Dobrițoiu, Elena Terecoasă, Lucian Negreanu, Cristina Tiu
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-02-01
Series:Frontiers in Neurology
Subjects:
multiple sclerosis
drug induced colitis
colitis
ocrelizumab
review
CD-20
Online Access:https://www.frontiersin.org/articles/10.3389/fneur.2025.1530438/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fneur.2025.1530438/full

Similar Items